Submissions for variant NM_020975.6(RET):c.1998G>C (p.Lys666Asn)

dbSNP: rs146646971

Total submissions: 10

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
Ambry Genetics	RCV000219014	SCV000274624	pathogenic	Hereditary cancer-predisposing syndrome	2022-03-22	criteria provided, single submitter	clinical testing	The p.K666N mutation (also known as c.1998G>C) is located in coding exon 11 of the RET gene. This alteration results from a G to C substitution at nucleotide position 1998. The lysine at codon 666 is replaced by asparagine, an amino acid with similar properties. This specific alteration was identified in one patient from a screen of 329 patients with sporadic paraganglioma or pheochromocytoma (Currás-Freixes M et al. J. Med. Genet., 2015 Oct;52:647-56). A similar alteration causing the same amino acid change (c.1998G>T p.K666N) was identified in eight unrelated index cases with medullary thyroid carcinoma (MTC) (Xu JY et al. Thyroid, 2016 Oct, epub). Analysis of the families from these 8 cases showed several additional family members who were carriers of the variant that also had either MTC or C-cell hyperplasia. Three carriers were shown to have normal pathology at ages 21, 30 and 30 years of age. Xu et al. conclude that this alteration is low penetrance MTC allele, with no evidence for association with other MEN2A pathogenic features of pheochromocytoma and parathyroid abnormalities. This same c.1998G>T p.K666N alteration was reported in a case of sporadic medullary thyroid cancer in a 65 year old female (Muzza M et al. Eur J Endocrinol. 2010 Apr;162(4):771-7). Further analysis by Muzza et al. demonstrated increased oncogenic potential as compared to wild type, as well as significant structural impact that was predicted to alter the transmembrane α-helix, likely changing the secondary structure of the protein. In addition, several other alterations at this same position (p.K666E, p.K666R, and p.K666M) have been identified in sporadic cases of MTC (Yamazaki M et al. Endocr. J. 2014 Nov;61(11):1141-4; Borrello MG et al. Endocr. Relat. Cancer, 2011 Aug;18:519-27), or in large pedigrees demonstrating segregation with MTC or C-cell hyperplasia (Ahmed SA et al. J Mol Diagn. 2005 May;7(2):283-8; Mastroianno S et al. Endocrine, 2011 Dec;40:481-5). Of note, The American Thyroid Association has designated p.K666E as a mutation with moderate risk for MTC,10% incidence of pheochromocytomas and no incidence of hyperparathyroidism (Wells SA et al. Thyroid 2015 Jun;25(6):567-610). As observed in the literature and Ambry internal data, p.K666N, is primarily associated with MTC and not other features of MEN2A. Based on the available evidence, this alteration is classified as a pathogenic mutation with moderate risk.
Invitae	RCV000556223	SCV000658430	pathogenic	Multiple endocrine neoplasia, type 2	2024-01-16	criteria provided, single submitter	clinical testing	This sequence change replaces lysine, which is basic and polar, with asparagine, which is neutral and polar, at codon 666 of the RET protein (p.Lys666Asn). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with medullary thyroid carcinoma, C-cell dysplasia, and elevated calcitonin levels and pheochromocytoma (PMID: 20103606, 26269449, 26687385, 27673361). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 230926). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Experimental studies have shown that this missense change affects RET function (PMID: 20103606). This variant disrupts the p.Lys666 amino acid residue in RET. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 15858153, 21690267). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.
Hadassah Hebrew University Medical Center	RCV000556223	SCV001572881	pathogenic	Multiple endocrine neoplasia, type 2	2019-06-20	criteria provided, single submitter	clinical testing
New York Genome Center	RCV001589145	SCV001815681	pathogenic	Familial medullary thyroid carcinoma	2020-09-23	criteria provided, single submitter	clinical testing	The inherited c.1998G>C,p.Lys666Asn missense variant identified in RET has been reported to segregate with medullary thyroid carcinoma, C-cell dysplasia, and elevated calcitonin levels in several families (PMID:27673361, 20103606). This variant has also been reported in individuals with pheochromocytoma (PMID:26269449) and breast cancer (PMID:26687385). This variant is present in population database (gnomAD v2.1) with a frequency of 0.002%. Experimental studies have shown that this missense variant results in increased RET phosphorylation activity and increased transformation potential in cell culture (PMID:20103606). Rare missense variants at the same codon (p.Lys666Glu, p.Lys666Met, p.Lys666Arg) have been reported in the individuals with medullary thyroid carcinoma and multiple endocrine neoplasia type II and suggests that the lysine residue is critical for RET protein function (PMID:15858153, 21690267, 21678021, 20516206, 25319874). Based on the available evidence, the inherited missense variant c.1998G>C,p.Lys666Asn in the RET gene is classified as Pathogenic.
Institute of Human Genetics, Clinical Exome/Genome Diagnostics Group, University Hospital Bonn	RCV002463360	SCV002757857	likely pathogenic	Multiple endocrine neoplasia, type 2b; Pheochromocytoma; Familial medullary thyroid carcinoma; Multiple endocrine neoplasia, type 2a	2022-11-10	criteria provided, single submitter	clinical testing
Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein	RCV003137821	SCV003807131	pathogenic	Multiple endocrine neoplasia, type 2a	2022-09-15	criteria provided, single submitter	clinical testing	ACMG classification criteria: PS1 strong, PS4 moderated, PM1 moderated, PM2 moderated
Baylor Genetics	RCV003462451	SCV004206739	pathogenic	Hirschsprung disease, susceptibility to, 1	2023-03-12	criteria provided, single submitter	clinical testing
Color Diagnostics, LLC DBA Color Health	RCV000556223	SCV004357238	likely pathogenic	Multiple endocrine neoplasia, type 2	2023-08-17	criteria provided, single submitter	clinical testing	This missense variant replaces lysine with asparagine at codon 666 of the RET protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). A functional study has reported that the variant protein, p.Lys666Asn, resulted in elevated phosphorylation of the ERK protein in transiently-transfected at a level that is intermediate between the wild-type protein and the pathogenic control p.Cys634Arg (PMID: 20103606). The protein variant p.Lys666Asn, caused by c.1998G>T or c.1998G>C, has been reported in more than 10 heterozygous individuals affected with medullary thyroid cancer and/or pheochromocytoma (PMID: 20103606, 22865907, 26269449, 27673361, 28946813, 29408964) and a homozygous carrier affected with bilateral medullary thyroid cancer and pheochromocytoma (PMID: 29408964). The protein change was also reported in an individual with Cowden syndrome clinical features (macrocephaly, lipoma, renal cancer, thyroid cancer, goiter and Hashimoto's thyroiditis) and pheochromocytoma (PMID: 29684080), and it was observed to segregate with medullary thyroid cancer, C-cell hyperplasia, elevated calcitonin and/or pheochromocytoma (PMID: 27673361, 29408964). This variant has been identified in 7/282120 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Based on the available evidence, this variant is classified as Likely Pathogenic.
PreventionGenetics, part of Exact Sciences	RCV003919888	SCV004728431	likely pathogenic	RET-related condition	2024-01-19	criteria provided, single submitter	clinical testing	The RET c.1998G>C variant is predicted to result in the amino acid substitution p.Lys666Asn. This variant has been reported in the heterozygous state in several individuals with a personal and family history of medullary thyroid cancer (MTC), and an in vitro assay showed it displayed high kinase and transforming activity (Muzza et al. 2010. PubMed ID: 20103606; Xu et al. 2016. PubMed ID: 27673361). This variant was also reported in a cohort of individuals with phaeochromocytoma (Curras-Freixes et al. 2015. PubMed ID: 26269449, supplementary data) and in cohorts of individuals with breast cancer (Bernstein-Molho et al. 2019. PubMed ID: 30980208; Yablonski-Peretz et al. 2016. PubMed ID: 26687385). Lastly, this variant was reported in the homozygous state in an individual with medullary thyroid cancer and bilateral pheochromocytoma; the patient's son, who carried this variant in the heterozygous state, also had MTC (Jaber et al. 2018. PubMed ID: 29408964). However, not all carriers of this variant were affected at the time of testing, suggesting potential incomplete penetrance or variable age at onset. Other amino acid substitutions at this position have been reported in individuals with MTC or pheochromocytoma, suggesting that this amino acid residue may be critical for function (Human Gene Mutation Database; https://www.hgmd.cf.ac.uk/). This variant has not been reported in a large population database, indicating this variant is rare. This variant is interpreted as pathogenic in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/230926/?new_evidence=true). This variant is interpreted as likely pathogenic.
GenomeConnect - Brain Gene Registry	RCV002265692	SCV002548536	not provided	Multiple endocrine neoplasia, type 2b; Familial medullary thyroid carcinoma; Multiple endocrine neoplasia, type 2a		no assertion provided	phenotyping only	Variant interpreted as Pathogenic and reported on 11-17-2020 by Lab or GTR ID New York Genome Center. Assertions are reported exactly as they appear on the patient provided laboratory report. GenomeConnect does not attempt to reinterpret the variant. The IDDRC-CTSA National Brain Gene Registry (BGR) is a study funded by the U.S. National Center for Advancing Translational Sciences (NCATS) and includes 13 Intellectual and Developmental Disability Research Center (IDDRC) institutions. The study is led by Principal Investigator John Constantino MD PhD from Washington University. The BGR is a data commons of gene variants paired with subject clinical information. This database helps scientists learn more about genetic changes and their impact on the brain and behavior. Participation in the Brain Gene Registry requires participation in GenomeConnect. More information about the Brain Gene Registry can be found on the study website - https://braingeneregistry.wustl.edu/.